Devices Neurosurgery Orthopaedic FDA

 News Release - November 26, 2007

Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System

SALT LAKE CITY, Nov. 26 (HSMN NewsFeed) -- Amedica Corporation, an orthopedic implants company focused on Silicon Nitride ceramic technologies, announced today that the U.S. Food and Drug Administration has granted 510(k) marketing clearance to Amedica's Valeo(TM) Pedicle Screw system.

The Valeo Pedicle Screw system is a low profile and modular pedicle screw system incorporating features that are aimed at allowing surgeons greater flexibility in the positioning of these spinal implants. The Valeo Pedicle Screw system is intended for non-cervical pedicle fixation from the T1 through L5 vertebral bodies of the spine as an adjunct to fusion. The implant and related instruments are designed to facilitate greater modularity and to better suit patient anatomy and achieve a consistent supplemental fixation outcome for many indications including degenerative disc disease, spinal stenosis and failed prior spine fusion surgery.

"FDA clearance of our Valeo Pedicle Screw System is another important milestone for Amedica," said Ashok Khandkar, Ph.D., Chief Executive Officer of Amedica Corporation. "Our pedicle screw system and recently cleared cervical plate will complement our line of innovative, Silicon Nitride ceramic spinal spacers, providing surgeons and patients with an important new option for spinal fixation."

About Amedica

Amedica Corporation is an emerging orthopedic implant company focused on using its Silicon Nitride ceramic technologies to develop and commercialize a broad range of innovative, high-performance spine and joint implants for the growing orthopedic device market. Its products under development include spine, reconstructive hip and knee implants that may represent a new standard of care in total joint implants based on superior durability, performance and safety.

Source: Amedica

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.